Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, ...

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ...

— Dr. David Ginn, Senior VP of Research and Development at Erroll McCoy AUGUSTA, GA, UNITED STATES, December 12, 2024 /EINPresswire.com/ -- Erroll McCoy is excited ...

Herpes simplex virus (HSV) is a widespread viral infection that affects millions of people globally. It can occur at any age, ...

Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent ...

In a recent study published in Communications Biology, researchers evaluated the therapeutic efficacy of Navoximod, combined with herpes simplex 1 (HSV-1) virotherapy, against hepatocellular carcinoma ...

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ...

Medically reviewed by Anju Goel, MD HSV-1 usually causes oral herpes, while HSV-2 primarily affects the genitals.Herpes often has no symptoms, so you may not know you are carrying the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Some studies found herpes simplex virus 1 increased ...

PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS) (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform ...